venBio

Pharvaris is a clinical-stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients. By targeting this clinically proven therapeutic target with novel small molecules, we are progressing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other B2 receptor-mediated indications. PHA121, Pharvaris’ lead drug candidate, is a novel and potent small-molecule bradykinin B2 receptor antagonist currently under Phase 1 clinical study. The co-founders of Pharvaris include an inventor of icatibant and the leadership from Jerini AG that developed icatibant for the treatment of HAE, now sold by Takeda under the brand name Firazyr®.

Apellis Pharmaceuticals, Inc. is an early stage biotechnology company focused on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (COPD). Apellis emerged from a successful transaction between Potentia Pharmaceuticals, Inc. and Alcon Research, Ltd in October 2009 in which Alcon licensed the ocular applications of Potentia’s family of complement inhibitors. Apellis holds the worldwide exclusive rights to the extra-ocular uses of these compounds. In May 2010, with start-up capital raised from private investors, Apellis commenced full-scale operations.

Turning Point Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company’s lead drug candidate repotrectinib is being evaluated in an ongoing Phase I/II trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+, or ALK+ advanced solid tumors. Its pipeline also includes multi-targeted drug candidates TPX-0046, a RET/SRC inhibitor; TPX-0022, a MET/CSF1R/SRC inhibitor; and TPX-0131, a preclinical ALK inhibitor. The company was founded in 2013 and is headquartered in San Diego, California.

RayzeBio, Inc. is a biotechnology company that develops tumor-targeted small molecule medicines that harness the power of radioisotopes. The company provides macrocyclic peptide mimetic binders to deliver therapeutic radioisotopes, such as Actinium-225, an alpha-emitter for solid tumors. RayzeBio, Inc. was founded in 2020 and is based in San Diego, California.

HistoWiz is a biotech company that automates the processing and digitizing of tissue samples for pharma and academia. Through its fully automated histology lab and the world’s first online pathologist network, HistoWiz processes and annotates tissue samples which are stored on PathologyMap, its cloud database, as a resource for cancer researchers. The data stored on PathologyMap enables the integration of technology and the development of AI tools for digital pathology on an unprecedented scale.

Apellis Pharmaceuticals, Inc. is an early stage biotechnology company focused on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (COPD). Apellis emerged from a successful transaction between Potentia Pharmaceuticals, Inc. and Alcon Research, Ltd in October 2009 in which Alcon licensed the ocular applications of Potentia’s family of complement inhibitors. Apellis holds the worldwide exclusive rights to the extra-ocular uses of these compounds. In May 2010, with start-up capital raised from private investors, Apellis commenced full-scale operations.

Checkmate Pharmaceuticals, Inc., a biotechnology company, develops novel immunotherapies for the treatment of cancer. It engages in the field of CpG oligonucleotides and validates an approach that combines the ability of CpG DNA to activate an anti-tumor T-cell response with checkpoint inhibition to overcome a tumor’s ability to mute the immune response. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

Impel NeuroPharma is a medical device company developing a novel drug delivery device that enables drugs to bypass the blood-brain barrier(BBB) using direct nose-to-brain delivery. It is focused on developing transformative therapies that unlock the full potential of therapeutic molecules for people living with CNS disorders with high unmet medical needs. The company was founded in 2008 and is headquartered in Seattle, Washington.

Precision BioSciences is a biotechnology company dedicated to improving lives through its next-generation gene editing technology, ARCUS. Precision BioSciences’ mission is to translate the world’s most powerful genome editing technology into greatly needed products throughout the life sciences. Precision’s proprietary ARCUS genome editing technology enables the production of highly specific nucleases that can insert, remove, and modify DNA at essentially any location in a complex genome.

ACELYRIN is a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of promising drug candidates and by leveraging its expertise to rapidly advance these medicines to patients.

Artiva Biotherapeutics, Inc., a biotech company, develops and manufactures cellular immunotherapies for cancer patients. The company offers a pipeline of off-the-shelf, allogeneic natural killer (NK) cell therapies for the treatment of hematologic cancers or solid tumors. The company’s products target CD20 and CD19 in B-cell lymphomas and HER2 in various solid tumors. The company was founded in 2019 and is headquartered in San Diego, California. Artiva Biotherapeutics, Inc. operates as a subsidiary of Green Cross Holdings Corporation.

RayzeBio, Inc. is a biotechnology company that develops tumor-targeted small molecule medicines that harness the power of radioisotopes. The company provides macrocyclic peptide mimetic binders to deliver therapeutic radioisotopes, such as Actinium-225, an alpha-emitter for solid tumors. RayzeBio, Inc. was founded in 2020 and is based in San Diego, California.

RayzeBio, Inc. is a biotechnology company that develops tumor-targeted small molecule medicines that harness the power of radioisotopes. The company provides macrocyclic peptide mimetic binders to deliver therapeutic radioisotopes, such as Actinium-225, an alpha-emitter for solid tumors. RayzeBio, Inc. was founded in 2020 and is based in San Diego, California.

NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics. The team leverages Structurally Engineered Fatty Acid (SEFA) technology to develop novel and unique therapeutic approaches targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generated pipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models.

ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer. It is an independent, private biotechnology company. The founding of Alexo Therapeutics was based upon technology invented by Aaron Ring, K. Christopher Garcia, Kipp Weiskopf, Aron Levin, and Irving Weissman at Stanford University. This discovery involves soluble versions of signal regulatory protein-α (SIRPα) that have been engineered to bind CD47 with significantly greater affinity than natural SIRPα.1.

Bellicum Pharmaceuticals is a clinical stage company developing next generation therapeutic vaccines and other immunotherapeutic approaches for the treatment of cancer and chronic infectious diseases. Bellicum's novel approach is to utilize precise knowledge of the signaling pathways that regulate the immune response to target specific factors that can influence the potency and duration of this response.

NFlection Therapeutics, Inc., a biotechnology company, focuses on the discovery and development of targeted therapies for rare disorders. It offers therapies, such as RASopathies that are driven by the aberrant activation of the Ras/Raf/MEK/ERK pathway. The company also develops soft mitogen-activated protein kinase (MEK) to mitigate and treat cutaneous neurofibromas in neurofibromatosis type 1. NFlection Therapeutics, Inc. was incorporated in 2014 and is based in Wayne, Pennsylvania.

Stargazer Pharmaceuticals Inc., a biopharmaceutical company, develops and manufactures therapies for eye diseases. It offers a treatment for Stargardt’s disease, a form of juvenile retinal degeneration. Stargazer Pharmaceuticals Inc. was founded in 2018 and is based in Boston, Massachusetts.

ACELYRIN is a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of promising drug candidates and by leveraging its expertise to rapidly advance these medicines to patients.

Cytos is a public biopharmaceutical company focused on the development of targeted immunotherapies with a VLP B-cell vaccines platform and ongoing preclinical development programs based on the platform.

Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients with systemic amyloidosis. Its proprietary peptide-based pan-amyloid targeting agents have the potential to diagnose and treat all forms and stages of systemic amyloidosis. The company is focused on targeting common pathology in all systemic amyloidosis diseases, with the goal of developing treatments for all subtypes of amyloidosis, including the majority in which there are currently no treatment options.

Swift Health Systems Inc., a medical device company, develops invisible orthodontic solutions. The company develops InBrace, an orthodontic system that is hidden behind the teeth to correct malocclusion (crooked teeth). Swift Health Systems Inc. was incorporated in 2014 and is based in Irvine, California.

Solstice Biologics is a biotech company that provides solutions for targeting and delivering nucleic acid therapeutics. The Company specializes in the development of small, cell-permeable RNAi pro-drugs that can enter many different cell types and deliver on the promise of RNAi therapeutics. It was established in 2012 and is based in San Francisco, California.

Precision BioSciences is a biotechnology company dedicated to improving lives through its next-generation gene editing technology, ARCUS. Precision BioSciences’ mission is to translate the world’s most powerful genome editing technology into greatly needed products throughout the life sciences. Precision’s proprietary ARCUS genome editing technology enables the production of highly specific nucleases that can insert, remove, and modify DNA at essentially any location in a complex genome.

Adaptimmune develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroys cancerous or infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was incorporated in 2007 and is based in Abingdon, United Kingdom.

Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients with systemic amyloidosis. Its proprietary peptide-based pan-amyloid targeting agents have the potential to diagnose and treat all forms and stages of systemic amyloidosis. The company is focused on targeting common pathology in all systemic amyloidosis diseases, with the goal of developing treatments for all subtypes of amyloidosis, including the majority in which there are currently no treatment options.

Aeovian Pharmaceuticals, Inc. develops and commercializes therapeutics for the treatment of age-related and other diseases. The company's therapeutics inhibit the mTORC1 and mTORC2 pathways that address the underlying causes of disease initiation and progression, such as oxidative, cellular, and environmental stress. Aeovian Pharmaceuticals, Inc. was formerly known as Delos Pharmaceuticals, Inc. The company was founded in 2012 and is based in San Francisco, California.

Checkmate Pharmaceuticals, Inc., a biotechnology company, develops novel immunotherapies for the treatment of cancer. It engages in the field of CpG oligonucleotides and validates an approach that combines the ability of CpG DNA to activate an anti-tumor T-cell response with checkpoint inhibition to overcome a tumor’s ability to mute the immune response. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

Pharvaris is a clinical-stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients. By targeting this clinically proven therapeutic target with novel small molecules, we are progressing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other B2 receptor-mediated indications. PHA121, Pharvaris’ lead drug candidate, is a novel and potent small-molecule bradykinin B2 receptor antagonist currently under Phase 1 clinical study. The co-founders of Pharvaris include an inventor of icatibant and the leadership from Jerini AG that developed icatibant for the treatment of HAE, now sold by Takeda under the brand name Firazyr®.

Impel NeuroPharma is a medical device company developing a novel drug delivery device that enables drugs to bypass the blood-brain barrier(BBB) using direct nose-to-brain delivery. It is focused on developing transformative therapies that unlock the full potential of therapeutic molecules for people living with CNS disorders with high unmet medical needs. The company was founded in 2008 and is headquartered in Seattle, Washington.

Turning Point Therapeutics, Inc. is a clinical-stage structure-based drug design company for the discovery and development of precision medicines for cancer and other diseases. We are focusing on the design of novel chemical identities for established oncogene drivers with secondary resistant mutations, newly identified disease-driven targets, and potential targets regulating tumor microenvironment and tumor immunity.

Labrys Biologics Inc., a company focused on treatments for chronic migraine. Labrys Biologics has acquired worldwide rights to RN-307 from Pfizer Inc. RN-307 is an antibody for the treatment of chronic migraine.

Metacrine is a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases. The most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. Beyond the FXR program, a pipeline of novel drug candidates against other drug targets is being explored by taking advantage of internal drug discovery and development capabilities.

RayzeBio, Inc. is a biotechnology company that develops tumor-targeted small molecule medicines that harness the power of radioisotopes. The company provides macrocyclic peptide mimetic binders to deliver therapeutic radioisotopes, such as Actinium-225, an alpha-emitter for solid tumors. RayzeBio, Inc. was founded in 2020 and is based in San Diego, California.

Neurogastrx, Inc. manufactures biopharmaceutical products for the treatment of gastrointestinal disorders. The company develops product such as NG101 that increases gastric motility and contains antiemetic properties. Neurogastrx, Inc. was incorporated in 2017 and is based in Campbell, California.

Stargazer Pharmaceuticals Inc., a biopharmaceutical company, develops and manufactures therapies for eye diseases. It offers a treatment for Stargardt’s disease, a form of juvenile retinal degeneration. Stargazer Pharmaceuticals Inc. was founded in 2018 and is based in Boston, Massachusetts.

Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients with systemic amyloidosis. Its proprietary peptide-based pan-amyloid targeting agents have the potential to diagnose and treat all forms and stages of systemic amyloidosis. The company is focused on targeting common pathology in all systemic amyloidosis diseases, with the goal of developing treatments for all subtypes of amyloidosis, including the majority in which there are currently no treatment options.

Akero Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for serious metabolic diseases. Its lead product candidate is AKR-001, which is in Phase IIa clinical trial for the treatment of nonalcoholic steatohepatitis disease.The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was founded in 2017 and is headquartered in South San Francisco, California.

Arrakis Therapeutics is a developer of a drug discovery platform intended to target RNA. The company's platform integrates leading-edge RNA bioinformatic and structural tools to produce a pipeline of rSMs to treat a range of disease including neurology, oncology and rare genetic diseases, enabling physicians to offer enhanced care.

Akero Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for serious metabolic diseases. Its lead product candidate is AKR-001, which is in Phase IIa clinical trial for the treatment of nonalcoholic steatohepatitis disease.The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was founded in 2017 and is headquartered in South San Francisco, California.

Heart Metabolics Limited is pioneering a pharmaceutical therapy for the treatment of hypertrophic cardiomyopathy (“HCM”). HCM is a condition in which the heart muscle becomes thick. The thickening makes it harder for blood to leave the heart forcing the heart to work harder to pump blood, leading in many cases to heart failure. Sudden death is caused frequently. There are over 100,000 cases of HCM in the United States alone, often presenting more severely in young adults and athletes; unfortunately the younger the individual is when diagnosed with HCM, the more likely that the individual has a severe form. Although various cardiovascular drugs are currently used to treat HCM, there are patients who are not being helped by current therapeutics. In response to this medical need and based on encouraging phase II clinical trial results to date, Heart Metabolics is developing perhexiline as a therapeutic for all types of HCM. Perhexiline is currently an approved drug in Australia and New Zealand for the treatment of angina. Heart Metabolics plans to conduct clinical trials in the U.S. and seek FDA approval of perhexiline as an orphan drug; the company currently has such an orphan designation from the FDA.

Checkmate Pharmaceuticals, Inc., a biotechnology company, develops novel immunotherapies for the treatment of cancer. It engages in the field of CpG oligonucleotides and validates an approach that combines the ability of CpG DNA to activate an anti-tumor T-cell response with checkpoint inhibition to overcome a tumor’s ability to mute the immune response. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

FogPharma derives financial support from a unique syndicate of extraordinary private and institutional investors. FogPharma’s network of friends includes our founders, employees, investors, advisors, collaborators, and cancer patients; all working together to pioneer a unique approach toward conquering cancer. FogPharma is laser-focused and unstoppable in its mission to deliver the new class of medicines to patients and their families to bring them years to life and life to years.

FogPharma derives financial support from a unique syndicate of extraordinary private and institutional investors. FogPharma’s network of friends includes our founders, employees, investors, advisors, collaborators, and cancer patients; all working together to pioneer a unique approach toward conquering cancer. FogPharma is laser-focused and unstoppable in its mission to deliver the new class of medicines to patients and their families to bring them years to life and life to years.

Arrakis Therapeutics is a developer of a drug discovery platform intended to target RNA. The company's platform integrates leading-edge RNA bioinformatic and structural tools to produce a pipeline of rSMs to treat a range of disease including neurology, oncology and rare genetic diseases, enabling physicians to offer enhanced care.

Ablaze Pharma is a clinical stage bio-pharmaceutical company that is focused on developing Targeted Radiotherapy (TRT) to benefit cancer patients.

Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing monoclonal antibody biosimilar therapeutics. It is advancing its pipeline of 11 biosimilar products, two of which are currently in clinical development. The company employs its BioSymphony biosimilars business model to achieve accelerated development and technical excellence in order to create affordable medicines for patients around the world.

Pharvaris is a clinical-stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients. By targeting this clinically proven therapeutic target with novel small molecules, we are progressing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other B2 receptor-mediated indications. PHA121, Pharvaris’ lead drug candidate, is a novel and potent small-molecule bradykinin B2 receptor antagonist currently under Phase 1 clinical study. The co-founders of Pharvaris include an inventor of icatibant and the leadership from Jerini AG that developed icatibant for the treatment of HAE, now sold by Takeda under the brand name Firazyr®.

CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, develops clinical candidates for cardiovascular, metabolic, and kidney diseases. It focuses on developing CIN-107, a aldosterone synthase inhibitor for the treatment of resistant hypertension and primary aldosteronism. The company was founded in 2018 and is based in Cincinnati, Ohio.

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients living with rare neurological disorders. Its lead product includes WAKIX (pitolisant) for the treatment of pediatric patients suffering from narcolepsy. Harmony Biosciences Holdings, Inc. was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. The company was founded in 2017 and is based in Plymouth Meeting, Pennsylvania.

Artiva Biotherapeutics, Inc., a biotech company, develops and manufactures cellular immunotherapies for cancer patients. The company offers a pipeline of off-the-shelf, allogeneic natural killer (NK) cell therapies for the treatment of hematologic cancers or solid tumors. The company’s products target CD20 and CD19 in B-cell lymphomas and HER2 in various solid tumors. The company was founded in 2019 and is headquartered in San Diego, California. Artiva Biotherapeutics, Inc. operates as a subsidiary of Green Cross Holdings Corporation.

Precision BioSciences is a biotechnology company dedicated to improving lives through its next-generation gene editing technology, ARCUS. Precision BioSciences’ mission is to translate the world’s most powerful genome editing technology into greatly needed products throughout the life sciences. Precision’s proprietary ARCUS genome editing technology enables the production of highly specific nucleases that can insert, remove, and modify DNA at essentially any location in a complex genome.

ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The Company's technology enables targeting loss-of-gene features of solid tumor cells, sparing normal, healthy tissues.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, as well as a range of solid tumor indications, including head and neck squamous cell and human epidermal growth factor receptor 2 positive gastric/gastroesophageal junction carcinoma. The company was founded in 2015 and is based in Burlingame, California.

Solstice Biologics is a biotech company that provides solutions for targeting and delivering nucleic acid therapeutics. The Company specializes in the development of small, cell-permeable RNAi pro-drugs that can enter many different cell types and deliver on the promise of RNAi therapeutics. It was established in 2012 and is based in San Francisco, California.

Tallac Therapeutics, Inc. develops immunotherapies for cancer patients. Tallac Therapeutics, Inc. was formerly known as Tollnine, Inc. The company was founded in 2018 and is based in Burlingame, California.

ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer. It is an independent, private biotechnology company. The founding of Alexo Therapeutics was based upon technology invented by Aaron Ring, K. Christopher Garcia, Kipp Weiskopf, Aron Levin, and Irving Weissman at Stanford University. This discovery involves soluble versions of signal regulatory protein-α (SIRPα) that have been engineered to bind CD47 with significantly greater affinity than natural SIRPα.1.

Stem Cell Therapeutics Corp. (TSX-V: SSS), a Toronto-based biopharmaceutical development company, is Canada’s only public company dedicated to advancing cancer stem cell discoveries into novel and innovative cancer therapies. Building on over half a century of leading groundbreaking Canadian stem cell research, we are supported by established links to multiple Toronto academic institutes and oncology treatment centres that represent one of the world’s most acclaimed cancer research hubs.

Tallac Therapeutics, Inc. develops immunotherapies for cancer patients. Tallac Therapeutics, Inc. was formerly known as Tollnine, Inc. The company was founded in 2018 and is based in Burlingame, California.

Silagene is a biotech company developing technology designed to facilitate the creation of U1 adaptors with therapeutic potential. The company's technology overcomes the limitations of gene silencing technologies, enabling doctors to to treat patients with various types of cancers. It was founded in 2008 and is based in Hillsborough, New Jersey, United States.

FogPharma derives financial support from a unique syndicate of extraordinary private and institutional investors. FogPharma’s network of friends includes our founders, employees, investors, advisors, collaborators, and cancer patients; all working together to pioneer a unique approach toward conquering cancer. FogPharma is laser-focused and unstoppable in its mission to deliver the new class of medicines to patients and their families to bring them years to life and life to years.

Neurogastrx, Inc. manufactures biopharmaceutical products for the treatment of gastrointestinal disorders. The company develops product such as NG101 that increases gastric motility and contains antiemetic properties. Neurogastrx, Inc. was incorporated in 2017 and is based in Campbell, California.

NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics. The team leverages Structurally Engineered Fatty Acid (SEFA) technology to develop novel and unique therapeutic approaches targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generated pipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models.

Ventyx Biosciences is a biotechnology company with a diverse portfolio of best-in-class highly differentiated clinical and pre-clinical stage programs focused on high-value targets.

RayzeBio, Inc. is a biotechnology company that develops tumor-targeted small molecule medicines that harness the power of radioisotopes. The company provides macrocyclic peptide mimetic binders to deliver therapeutic radioisotopes, such as Actinium-225, an alpha-emitter for solid tumors. RayzeBio, Inc. was founded in 2020 and is based in San Diego, California.

Elevation Oncology, Inc., a biotechnology company, focuses on the development of precision medicines for patients with genomically defined cancers. It offers drugs that inhibit the specific alterations identified as drivers of cancer; and treats solid tumors with the NRG1 genomic fusion. Elevation Oncology, Inc. was formerly known as 14ner Oncology, Inc. The company was incorporated in 2019 and is based in New York, New York.

Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The company is currently developing voclosporin, an investigational drug, for the potential treatment of lupus nephritis, focal segmental glomerulosclerosis, and Dry Eye Syndrome. The company is headquartered in Victoria, British Columbia and focuses its development efforts globally.

Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing monoclonal antibody biosimilar therapeutics. It is advancing its pipeline of 11 biosimilar products, two of which are currently in clinical development. The company employs its BioSymphony biosimilars business model to achieve accelerated development and technical excellence in order to create affordable medicines for patients around the world.

Checkmate Pharmaceuticals, Inc., a biotechnology company, develops novel immunotherapies for the treatment of cancer. It engages in the field of CpG oligonucleotides and validates an approach that combines the ability of CpG DNA to activate an anti-tumor T-cell response with checkpoint inhibition to overcome a tumor’s ability to mute the immune response. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

As of March 9, 2020, Menlo Therapeutics Inc. was acquired by Foamix Pharmaceuticals Ltd., in a reverse merger transaction. Menlo Therapeutics Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis; psoriasis; chronic pruritus; atopic dermatitis; and refractory chronic cough. The company was formerly known as Tigercat Pharma, Inc. and changed its name to Menlo Therapeutics Inc. in May 2016. Menlo Therapeutics Inc. was founded in 2011 and is headquartered in Redwood City, California.

Checkmate Pharmaceuticals, Inc., a biotechnology company, develops novel immunotherapies for the treatment of cancer. It engages in the field of CpG oligonucleotides and validates an approach that combines the ability of CpG DNA to activate an anti-tumor T-cell response with checkpoint inhibition to overcome a tumor’s ability to mute the immune response. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

NFlection Therapeutics, Inc., a biotechnology company, focuses on the discovery and development of targeted therapies for rare disorders. It offers therapies, such as RASopathies that are driven by the aberrant activation of the Ras/Raf/MEK/ERK pathway. The company also develops soft mitogen-activated protein kinase (MEK) to mitigate and treat cutaneous neurofibromas in neurofibromatosis type 1. NFlection Therapeutics, Inc. was incorporated in 2014 and is based in Wayne, Pennsylvania.

Metacrine is a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases. The most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. Beyond the FXR program, a pipeline of novel drug candidates against other drug targets is being explored by taking advantage of internal drug discovery and development capabilities.

Elevation Oncology, Inc., a biotechnology company, focuses on the development of precision medicines for patients with genomically defined cancers. It offers drugs that inhibit the specific alterations identified as drivers of cancer; and treats solid tumors with the NRG1 genomic fusion. Elevation Oncology, Inc. was formerly known as 14ner Oncology, Inc. The company was incorporated in 2019 and is based in New York, New York.

Pharvaris is a clinical-stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients. By targeting this clinically proven therapeutic target with novel small molecules, we are progressing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other B2 receptor-mediated indications. PHA121, Pharvaris’ lead drug candidate, is a novel and potent small-molecule bradykinin B2 receptor antagonist currently under Phase 1 clinical study. The co-founders of Pharvaris include an inventor of icatibant and the leadership from Jerini AG that developed icatibant for the treatment of HAE, now sold by Takeda under the brand name Firazyr®.

Akero Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for serious metabolic diseases. Its lead product candidate is AKR-001, which is in Phase IIa clinical trial for the treatment of nonalcoholic steatohepatitis disease.The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was founded in 2017 and is headquartered in South San Francisco, California.

Cidara Therapeutics is a biotechnology company that specializes in the fields of healthcare and therapeutics. The company focuses on developing innovative therapies to treat life-threatening illnesses exacerbated by deficiencies of the human immune system. Cidara Therapeutics was founded in 2012 and headquartered in San Diego, California.

ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer. It is an independent, private biotechnology company. The founding of Alexo Therapeutics was based upon technology invented by Aaron Ring, K. Christopher Garcia, Kipp Weiskopf, Aron Levin, and Irving Weissman at Stanford University. This discovery involves soluble versions of signal regulatory protein-α (SIRPα) that have been engineered to bind CD47 with significantly greater affinity than natural SIRPα.1.

Aeovian Pharmaceuticals, Inc. develops and commercializes therapeutics for the treatment of age-related and other diseases. The company's therapeutics inhibit the mTORC1 and mTORC2 pathways that address the underlying causes of disease initiation and progression, such as oxidative, cellular, and environmental stress. Aeovian Pharmaceuticals, Inc. was formerly known as Delos Pharmaceuticals, Inc. The company was founded in 2012 and is based in San Francisco, California.

Seragon Pharmaceuticals, Inc., headquartered in Irvine, California, is a research-based biopharmaceutical company dedicated to improving human and animal health through innovative science. Seragon Pharmaceuticals is committed to applying cutting-edge scientific and technological advancements to the fields of metabolism, gene therapy and bioinformatics. From the research end to consumer products and clinical applications, Seragon strives to bring people access to the most significant breakthroughs in medicine. For more information, please visit www.seragon.com

Checkmate Pharmaceuticals, Inc., a biotechnology company, develops novel immunotherapies for the treatment of cancer. It engages in the field of CpG oligonucleotides and validates an approach that combines the ability of CpG DNA to activate an anti-tumor T-cell response with checkpoint inhibition to overcome a tumor’s ability to mute the immune response. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

Artiva Biotherapeutics, Inc., a biotech company, develops and manufactures cellular immunotherapies for cancer patients. The company offers a pipeline of off-the-shelf, allogeneic natural killer (NK) cell therapies for the treatment of hematologic cancers or solid tumors. The company’s products target CD20 and CD19 in B-cell lymphomas and HER2 in various solid tumors. The company was founded in 2019 and is headquartered in San Diego, California. Artiva Biotherapeutics, Inc. operates as a subsidiary of Green Cross Holdings Corporation.

Neurogastrx, Inc. manufactures biopharmaceutical products for the treatment of gastrointestinal disorders. The company develops product such as NG101 that increases gastric motility and contains antiemetic properties. Neurogastrx, Inc. was incorporated in 2017 and is based in Campbell, California.

Aragon Pharmaceuticals is a discovery-stage small molecule company focused on therapeutics for the treatment of hormone-resistant cancers, with an initial focus on prostate and breast cancer.

Swift Health Systems Inc., a medical device company, develops invisible orthodontic solutions. The company develops InBrace, an orthodontic system that is hidden behind the teeth to correct malocclusion (crooked teeth). Swift Health Systems Inc. was incorporated in 2014 and is based in Irvine, California.

Metacrine is a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases. The most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. Beyond the FXR program, a pipeline of novel drug candidates against other drug targets is being explored by taking advantage of internal drug discovery and development capabilities.

Swift Health Systems Inc., a medical device company, develops invisible orthodontic solutions. The company develops InBrace, an orthodontic system that is hidden behind the teeth to correct malocclusion (crooked teeth). Swift Health Systems Inc. was incorporated in 2014 and is based in Irvine, California.

Metacrine is a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases. The most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. Beyond the FXR program, a pipeline of novel drug candidates against other drug targets is being explored by taking advantage of internal drug discovery and development capabilities.

Esker is a precision medicines company looking to eliminate the “all-comers” approach that is seen with today’s treatments for people with autoimmune disease. Even with the innovation of the last decade, many patients continue to cycle through the approved therapies while continuing to look for the right therapy to alleviate the impact of their disease without life-impacting side effects. Esker leverages a precision analytics platform, powered by Foresite Labs, coupled with a team of experts with deep experience in precision medicine drug development and immunology, in order to create medicines that change the lives of people with autoimmune disease.

Aeovian Pharmaceuticals, Inc. develops and commercializes therapeutics for the treatment of age-related and other diseases. The company's therapeutics inhibit the mTORC1 and mTORC2 pathways that address the underlying causes of disease initiation and progression, such as oxidative, cellular, and environmental stress. Aeovian Pharmaceuticals, Inc. was formerly known as Delos Pharmaceuticals, Inc. The company was founded in 2012 and is based in San Francisco, California.

Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients with systemic amyloidosis. Its proprietary peptide-based pan-amyloid targeting agents have the potential to diagnose and treat all forms and stages of systemic amyloidosis. The company is focused on targeting common pathology in all systemic amyloidosis diseases, with the goal of developing treatments for all subtypes of amyloidosis, including the majority in which there are currently no treatment options.

Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers. Its targeted radiotherapies utilize purpose-built vectors to specifically target high-energy radio-isotopes to tumors and metastatic cancer lesions. This new class of drugs holds tremendous untapped therapeutic and commercial potential, and has generated over $10B in recent M&A, financings, and product launches – and are expected to comprise 70% of the $30B nuclear medicine market by 2030. It was launched by adMare BioInnovations, Canada’s global life sciences venture, in partnership with industry leaders AbCellera, and some of the country’s most successful scientist entrepreneurs.

Pharvaris is a clinical-stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients. By targeting this clinically proven therapeutic target with novel small molecules, we are progressing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other B2 receptor-mediated indications. PHA121, Pharvaris’ lead drug candidate, is a novel and potent small-molecule bradykinin B2 receptor antagonist currently under Phase 1 clinical study. The co-founders of Pharvaris include an inventor of icatibant and the leadership from Jerini AG that developed icatibant for the treatment of HAE, now sold by Takeda under the brand name Firazyr®.

Impel NeuroPharma, Inc. develops a drug delivery device for central nervous system (CNS) disorders. The company’s drug delivery platform administers medicine into the nasal cavity. The company has a strategic alliance with 3M Drug Delivery Systems. Impel NeuroPharma, Inc. was incorporated in 2008 and is based in Seattle, Washington.